The liberated domain I of urokinase plasminogen activator receptor - a new tumour marker in small cell lung cancer

APMIS

Volumn 121, Issue 3, 2013, Pages 189-196

  Almasi, Charlotte E ^a   Drivsholm, Lars ^c   Pappot, Helle ^d   Høyer Hansen, Gunilla ^a,b   Christensen, Ib J ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Section of Endocrinology   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Cleaved uPAR; Prognosis; Small cell lung carcinoma; Time resolved fluorescence immunoassays; uPAR

Indexed keywords

LACTATE DEHYDROGENASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADULT; AGED; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGRESSION ANALYSIS; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84874188834     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02955.x     Document Type: Article

References (42)

1. Skuladottir H, Olesen JH, Hirsch FR. Incidence of lung cancer in Denmark: historical and actual status. Lung Cancer 1999;27:107-18.
2. The US National Cancer Institute, Surveillance Epidemiology and End Results, Cancer Statistics Review 1975-2009 (Vintage 2009 Population). http://seer.cancer.gov/csr/1975_2009_pops09/ [accessed on 30 2012]
3. Hermes A, Waschki B, Gatzemeier U, Reck M. Characteristics, treatment patterns and outcomes of patients with small cell lung cancer-a retrospective single institution analysis. Lung Cancer 2011;71:363-6.
4. Kreisman H, Wolkove N, Quoix E. Small-cell lung cancer presenting as a solitary pulmonary nodule. Chest 1992;101:225-31.
5. Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small-cell lung cancer: time to reevaluate. J Thorac Oncol 2008;3:1267-71.
6. Rostad H, Naalsund A, Jacobsen R, Strand TE, Scott H, Heyerdahl SE, et al. Small-cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 2004;26:782-6.
7. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
8. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
9. Behrendt N, Rønne E, Danø K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996;271:22885-94.
10. Høyer-Hansen G, Behrendt N, Ploug M, Danø K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997;420:79-85.
11. Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
12. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brunner N, et al. Receptor for urokinase is present in tumour-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
13. Usher PA, Thomsen OF, Iversen P, Johnsen M, Brünner N, Høyer-Hansen G, et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 2005;113:870-80.
14. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
15. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
16. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
17. Plebani M, Herszenyi L, Carraro P, De PM, Roveroni G, Cardin R, et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 1997;15:418-25.
18. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumour tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-41.
19. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55.
20. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
21. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997;243:21-6.
22. Høyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007;44:65-102.
23. Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K, Pappot H. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 2005;48:349-55.
24. Almasi CE, Høyer-Hansen G, Christensen IJ, Pappot H. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small-cell lung cancer. APMIS 2009;117:755-61.
25. Almasi CE, Christensen IJ, Høyer-Hansen G, Danø K, Pappot H, Dienemann H, et al. Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 2011;74:510-5.
26. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Lund IK. Cleaved forms of the urokinase plasminogen activator receptor in plasma enhance discrimination of benign from malignant disease and predict survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-93.
27. Thurison T, Lomholt AF, Rasch MG, Lund IK, Nielsen HJ, Christensen IJ, et al. A new assay for the measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer. Clin Chem 2010;56:1636-40.
28. Almasi CE, Brasso K, Iversen P, Pappot H, Høyer-Hansen G, Danø K, et al. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic pprostae cancer. Prostate 2011;71:899-907.
29. Hirsch FR, Dombernowsky P, Hansen HH. Treatment of small-cell lung cancer: the Copenhagen experience. Anticancer Res 1994;14:317-9.
30. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004;46:333-40.
31. Piironen T, Laursen B, Pass J, List K, Gårdsvoll H, Ploug M, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004;50:2059-68.
32. Henneke I, Greschus S, Savai R, Korfei M, Markart P, Mahavadi P, et al. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med 2010;181:611-9.
33. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, et al. Identification of uPAR-positive chemoresistant cells in small-cell lung cancer. PLoS One 2007;2:e243.
34. Buttery RC, Rintoul RC, Sethi T. Small-cell lung cancer: the importance of the extracellular matrix. Int J Biochem Cell Biol 2004;36:1154-60.
35. Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007;83:733-41.
36. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006;63:1028-37.
37. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
38. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 2002;99:1359-64.
39. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000;60:7126-32.
40. Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small-cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003;39:303-13.
41. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small-cell lung cancer. Lung Cancer 2003;39:131-8.
42. Sørensen M, Pijls-Johannesma M, Felip E. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v120-5.